Colorado State University Animal Cancer Center
Advancing Cancer Research
 
| Share

Cancer Research Supercluster / NeoTREX®

Cancer Supercluster RFP documents

>> Summary Information for 2010-2011 Cancer Supercluster RFP

Global challenges transcend conventional academic organizational structure. That’s where Colorado State University’s new model of public-private partnering is leading the way. Offering answers to far-reaching questions, the Supercluster concept unites experts from a broad array of research disciplines with a shared goal of finding real world solutions to global challenges and accelerating them to the marketplace.

Business Enterprise ArmThe Superclusters emulate proven business practices to harness the creative energies of Colorado State University’s academic research community. Each Supercluster has a Chief Scientific Officer who focuses on developing product-driven strategies with the academic research community. The Chief Operating Officer runs a business enterprise arm that advances emerging products by partnering with private and public sector organizations. Patents, licenses, partnerships and startup companies are the focus of the business arm as specialists of both marketplace and university research work to translate discoveries into products.

Cancer is the leading cause of death in pet animals and is a leading cause of death in people. Addressing this global challenge, Colorado State University’s Cancer Supercluster brings together scientists and scholars at the forefront of research from multiple departments and colleges. In addition, unique university infrastructure and capabilities, such as a fully developed clinical trials and tissue archiving program are optimally leveraged. Scholarly excellence in this extraordinary research environment fosters creativity in promoting product and policy development with potential for global impact.


Main Features of the Cancer Supercluster:

150 Faculty and Research Staff
$40 Million in Annual Research Funding

  • Internationally Recognized Research
  • Cancer Biology
  • Musculoskeletal Oncology
  • Experimental Therapeutics
  • Pharmacology
  • Tissue Archive of Canine and Feline Tumors
  • Cancer Immunology
  • Full Imaging and Radiation Therapy Capabilities
  • Molecular Genetics

Specific Resources or Facilities

Animal Cancer Center Research Resources

  • Pharmacokinetics and Pharmacodynamics Core
  • Proteomics and Metabolomics Core
  • Genomics Core
  • Flow Cytometry and Clinical Immunology Service
  • Bioinformatics
  • Full suite of imaging equipment secluding: MRI CT, radiography, PET/CT pending in 2009
  • Large caseload of clinical patients (canine and feline) with spontaneously occurring tumors are our research model.
  • Fully developed clinical oncology program with services in surgical, medical and radiation oncology
  • Varian Trilogy Linear Accelerator

Experimental Therapeutics Laboratory
Molecular Genetics Laboratory
Musculoskeletal Biology and Oncology Research Group and Laboratory
Tissue Archive of Canine and Feline Tumors
Core Member of the Clinical Oncology Trials Consortium

NeoTREX® / Cancer Supercluster Team

Please visit NeoTREX for more information.

Dr. Terry Opgenorth
Chief Operating Officer
NeoTREX
tjo@neotrex.org
(970) 297.5100

Dr. Steve Withrow
Chief Scientific Officer
NeoTREX
stephen.withrow@colostate.edu
(970) 297.4175

Stephen Foster
Director, Business Development
NeoTREX
steve@neotrex.org
(970) 297-1276

Dr. Christine Hardy
Director, Partnership Development
NeoTREX
christine.hardy@colostate.edu
(970) 297-5012